论文部分内容阅读
目的观察乙型合并丙型肝炎病毒感染的临床特点,并研究相关抗病毒治疗的策略。方法选取医院收治的乙型合并丙型肝炎病毒感染患者30例为观察组,单纯乙型肝炎病毒感染患者30例为对照组,回顾性分析临床病毒学、流行病学等相关资料及其临床特征。同时采取利巴韦林药物与PEGFNα-2a(人工重组干扰素)联合治疗,观察病毒学特点、病毒学应答率、复发率及不良反应情况。结果观察组HCV优势病毒株占90%,混合优势病毒株占16.67%,观察组HBe Ag阳性率为23.33%,低于对照组的53.33%(P<0.05)。结束治疗时,观察组病毒学总应答率为86.67%,高于对照组的63.33%(P<0.05);观察组复发率为46.67%,高于对照组的16.67%(P<0.05);观察组的不良反应发生率为43.33%,高于对照组的16.67%(P<0.05)。结论乙型合并丙型肝炎病毒感染的优势病毒株为丙型肝炎病毒,乙型肝炎病毒株的复制受丙型肝炎病毒株的抑制,乙型合并丙型肝炎病毒患者采取利巴韦林药物与PEGFNα-2a联合治疗病毒学应答率高,但是较易复发,不良反应发生率较高。
Objective To observe the clinical characteristics of hepatitis B combined with hepatitis C virus infection and to study the strategies of antiretroviral therapy. Methods Thirty patients with hepatitis B and C infection were selected as the observation group and 30 patients with hepatitis B virus infection as the control group. The clinical virological, epidemiological and other clinical data were retrospectively analyzed . At the same time taking ribavirin drug and PEGFNα-2a (artificial recombinant interferon) combined treatment, observation of virological characteristics, virological response rate, recurrence rate and adverse reactions. Results In the observation group, HCV dominant virus accounted for 90% and mixed dominant virus accounted for 16.67%. The positive rate of HBeAg in the observation group was 23.33%, which was lower than that of the control group (53.33%, P <0.05). At the end of treatment, the virological response rate in observation group was 86.67%, higher than that in control group (63.33%, P <0.05). The recurrence rate in observation group was 46.67%, which was higher than that in control group (16.67%, P <0.05) The incidence of adverse reactions in the group was 43.33%, which was higher than that in the control group (16.67%, P <0.05). Conclusion The predominant hepatitis B virus co-infected with hepatitis B virus is Hepatitis C virus, the replication of hepatitis B virus is inhibited by hepatitis C virus strain, and ribavirin is used in patients with hepatitis B and C PEGFNα-2a combination therapy virological response rate, but more likely to relapse, the incidence of adverse reactions higher.